Utama › Hipertensi Arteri Pulmonari › California
Kajian klinikal Hipertensi Arteri Pulmonari di California
12 kajian untuk Hipertensi Arteri Pulmonari sedang mencari peserta di lokasi di California.
Bandar di California
- Mountain View7 kajian
- Los Angeles4 kajian
- Sacramento3 kajian
- Santa Barbara3 kajian
- San Francisco3 kajian
Teks kajian rasmi (Bahasa Inggeris)
A Clinical Study of Sotatercept (MK-7962) in People With Pulmonary Arterial Hypertension (MK-7962-038)
- UC Davis - Medial Center ( Site 1064), Sacramento
Mengambil pesertaFasa 3
Umur 18 ke atas · Semua jantina · Dikemas kini 1 Okt 2026 · NCT07218029A Study to Evaluate the Efficacy and Safety of Once Daily Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Arterial Hypertension (PAH)
- USA012, Los Angeles
- USA008, Santa Barbara
- USA005, Torrance
Mengambil pesertaFasa 3
Umur 18 hingga 75 · Semua jantina · Dikemas kini 16 Sep 2026 · NCT07481981An Adaptive Program of IKT-001 in Pulmonary Arterial Hypertension (PAH)
- Cedars Sinai, Beverly Hills
- Jeffrey S. Sager, MD Medical Corporation, Santa Barbara
- Lundquist at Harbor UCLA, Torrance
Mengambil pesertaFasa 3
Umur 18 hingga 75 · Semua jantina · Dikemas kini 2 Sep 2026 · NCT07365332Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)
- Lucile Packard Children's Hospital, Palo Alto
Mengambil pesertaKajian pemerhatianSukarelawan sihat dialu-alukan
Umur 0 hingga 20 · Semua jantina · Dikemas kini 21 Ogo 2026 · NCT04278404A Study of ROC-101 in Patients With Pulmonary Arterial Hypertension (PAH) and Pulmonary Hypertension Associated With Interstitial Lung Disease (ILD-PH) (ROCSTAR STUDY)
- University of California Davis Health, Rancho Cordova
Mengambil pesertaFasa 2
Umur 18 hingga 80 · Semua jantina · Dikemas kini 10 Ogo 2026 · NCT07175038Open-label Extension Study of Seralutinib in Adult Subjects With PAH (PROSERA-EXT)
- Valley Advanced Lung Diseases Institute, Fresno
- Department of Veterans Affairs Greater Los Angeles Healthcare System, Los Angeles
- UC Davis Health Medical Center, Sacramento
- dan 1 lagi
Mengambil pesertaFasa 3
Umur 18 hingga 75 · Semua jantina · Dikemas kini 29 Jul 2026 · NCT06274801A Study to Learn About the Treatment LTP001 in Healthy Participants (Part A) and in Participants With PAH (Part B)
- UC Irvine Medical Center, Orange
- Stanford Medical Center, Stanford
Mengambil pesertaFasa 1/2Sukarelawan sihat dialu-alukan
Umur 18 hingga 100 · Semua jantina · Dikemas kini 21 Jul 2026 · NCT06649110A Study Evaluating the Safety and Tolerability of Artesunate in Patients With Pulmonary Arterial Hypertension
- Stanford University, Stanford
Mengambil pesertaFasa 1
Umur 18 hingga 60 · Semua jantina · Dikemas kini 23 Apr 2026 · NCT06872112Study to Evaluate Sotatercept (MK-7962) in Children With Pulmonary Arterial Hypertension (PAH) (MK-7962-008)
- The Regents of the University of California - Los Angeles (UCLA Pediatrics) ( Site 1606), Los Angeles
- Stanford University School of Medicine ( Site 1603), Palo Alto
- UCSF Benioff Children's Hospital San Francisco ( Site 1611), San Francisco
Mengambil pesertaFasa 2
Umur 1 hingga 17 · Semua jantina · Dikemas kini 20 Apr 2026 · NCT05587712Pulmonary Hypertension Association Registry
- UC Davis Health, Sacramento
- UCSF Medical Center, San Francisco
- UCSF Benioff Children's Hospital, San Francisco
- dan 2 lagi
Mengambil pesertaKajian pemerhatian
Umur 0 ke atas · Semua jantina · Dikemas kini 14 Nov 2025 · NCT04071327Treatment of Pulmonary Arterial Hypertension Using the Aria CV Pulmonary Hypertension System
- University of California-Los Angeles, Los Angeles
Mengambil peserta
Umur 18 ke atas · Semua jantina · Dikemas kini 29 Sep 2025 · NCT04555161Pediatric Pulmonary Hypertension Network (PPHNet) Informatics Registry
- Stanford University Medical Center, Palo Alto
- University California San Francisco, San Francisco
Mengambil pesertaKajian pemerhatian
1 Day – 21 Years · Semua jantina · Dikemas kini 13 Mac 2025 · NCT02249923Daripada ClinicalTrials.gov, data diperoleh pada 6 Okt 2026. Setiap kajian menetapkan kriteria kelayakannya sendiri; pasukan kajian menentukan siapa yang layak menyertai.